Orchids Paper Products (NYSEMKT:TIS) continues to be a company that has rewarded investor patience with solid execution. As a growing player in the large private label market for paper personal care products (paper towels, toilet paper, tissues, etc.), Orchids has not only been focusing on expanding its geographical reach and customer base, but also its product line up. Even more importantly, at least from my point of view, the company has continued to find ways to drive costs out of its processes and improve operating efficiencies.
Management's performance has not gone unrewarded, with the shares up another 20% since my last write-up and up close to 50% over the past year. Better still, there are solid reasons to feel good about the company's future - the expansion into the West Coast with Fabrica has gone better than expected, a new plant in Barnwell will be coming on line (in segments) this year, and Orchids is still only a small player in a large market (annualized revenue in the $200 million range out of a total private label addressable market opportunity in excess of $3 billion). Moreover, this is not a company I'd bet against when it comes to finding better ways to make better margins from its business.
All of that said, the valuation is no longer what I'd call a clear bargain. I never like to bet against good companies, and I'm definitely NOT recommending exiting a position here, but even double-digit annualized revenue growth and mid-teens FCF margin projects don't support a substantially higher fair value. I'll be the first to acknowledge that good companies deserve premiums and that a company like Orchids can outperform expectations, but I think the margin of safety here is smaller than I personally like for new positions.
Continue here for more:
Orchids Executing Well, But The Valuation Already In Bloom